Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) said on Monday two of its posters related to its patented synthetic cannabidiol (CBD) gel will be presented at the 70th annual meeting of the American Epilepsy Society next month.
The clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments said posters feature the company’s ZYN002 gel and include safety, tolerability and effects on cognition and mood changes in healthy volunteers and adult epilepsy patients with focal seizures.
The meeting will be held December 2 – 6 in Houston, Texas.
“We are encouraged to see that data further supporting the safety profile of ZYN002 were chosen for presentation at this year’s Annual Meeting for the American Epilepsy Society,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba.
“These data demonstrate that ZYN002 CDB gel is safe, well-tolerated and show no psychoactive effects across a wide range of doses. Enrollment in our STAR 1 phase 2 clinical trial for adult refractory epilepsy patients with focal seizures is continuing and we remain on track to report top line results of this trial in the first half of 2017. Earlier this month, we announced the initiation of our STAR 2 open-label extension trial which will support long-term safety and tolerability of ZYN002 CBD gel in this patient population.”
Zynerba shares, which closed on the half-day of trading on Friday down 1.8% at $14.04 were up 1.1% at $14.20 pre-market on Monday.
Story by ProactiveInvestors